CARTER ROBERT B 4

What Happened

• Robert B. Carter, a director of Quest Diagnostics (DGX), was granted an award of 1,142 shares on 2026-05-20. The Form 4 reports the acquisition as an award (code A) at a reported price of $0.00 (total $0), indicating these are compensation units rather than an open-market purchase.

Key Details

• Transaction date: 2026-05-20; Form filed: 2026-05-21 (timely).
• Transaction type: Award (code A); price per share reported: $0.00; reported amount: 1,142 shares.
• Footnote: F1 — represents an award of restricted stock units (RSUs).
• Shares owned after transaction: Not specified in this filing.
• No indication of a 10b5-1 plan, tax withholding, or sale associated with this transaction in the filing.

Context

• RSU awards are a common form of equity compensation for directors and typically vest over time or upon meeting service/other conditions; they do not represent immediately tradable shares until vested and delivered. This transaction reflects compensation/retention rather than a market purchase or sale and does not by itself indicate the director's view on the company's stock.